Isoxicam | CAS#34552-84-6

MedKoo Cat#: 341568 | Name: Isoxicam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Isoxicam is a biochemical.

Chemical Structure

Isoxicam

CAS#34552-84-6

Theoretical Analysis

MedKoo Cat#: 341568

Name: Isoxicam

CAS#: 34552-84-6

Chemical Formula: C14H13N3O5S

Exact Mass: 335.0576

Molecular Weight: 335.33

Elemental Analysis: C, 50.15; H, 3.91; N, 12.53; O, 23.86; S, 9.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Isoxicam; W 8495; W-8495; W8495; BRN 0577221.

IUPAC/Chemical Name

2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-, 1,1-dioxide

InChi Key

YYUAYBYLJSNDCX-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)

SMILES Code

O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NOC(C)=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 335.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fornells E, Fuguet E, Mañé M, Ruiz R, Box K, Bosch E, Ràfols C. Effect of vinylpyrrolidone polymers on the solubility and supersaturation of drugs; a study using the Cheqsol method. Eur J Pharm Sci. 2018 May 30;117:227-235. doi: 10.1016/j.ejps.2018.02.025. Epub 2018 Feb 23. PubMed PMID: 29481859. 2: Klimenko K. R-based Tool for a Pairwise Structure-activity Relationship Analysis. Mol Inform. 2018 Apr;37(4):e1700094. doi: 10.1002/minf.201700094. Epub 2017 Oct 25. PubMed PMID: 29068147. 3: Goswami S, Majumdar A, Sarkar M. Painkiller Isoxicam and Its Copper Complex Can Form Inclusion Complexes with Different Cyclodextrins: A Fluorescence, Fourier Transform Infrared Spectroscopy, and Nuclear Magnetic Resonance Study. J Phys Chem B. 2017 Sep 14;121(36):8454-8466. doi: 10.1021/acs.jpcb.7b05649. Epub 2017 Aug 29. PubMed PMID: 28806512. 4: Goswami S, Ray S, Sarkar M. Spectroscopic studies on the interaction of DNA with the copper complexes of NSAIDs lornoxicam and isoxicam. Int J Biol Macromol. 2016 Dec;93(Pt A):47-56. doi: 10.1016/j.ijbiomac.2016.08.025. Epub 2016 Aug 20. PubMed PMID: 27554932. 5: Majumdar A, Kundu D, Sarkar M. Differential Effect of Oxicam Non-Steroidal Anti-Inflammatory Drugs on Membranes and Their Consequence on Membrane Fusion. J Phys Chem B. 2015 Jul 30;119(30):9627-39. doi: 10.1021/acs.jpcb.5b03918. Epub 2015 Jul 21. PubMed PMID: 26147344. 6: Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec;66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23. Review. PubMed PMID: 25537198; PubMed Central PMCID: PMC5300000. 7: Xu S, Hermanson DJ, Banerjee S, Ghebreselasie K, Clayton GM, Garavito RM, Marnett LJ. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network. J Biol Chem. 2014 Mar 7;289(10):6799-808. doi: 10.1074/jbc.M113.517987. Epub 2014 Jan 14. PubMed PMID: 24425867; PubMed Central PMCID: PMC3945341. 8: Martínez-Araya JI, Salgado-Morán G, Glossman-Mitnik D. Computational nanochemistry report on the oxicams--conceptual DFT indices and chemical reactivity. J Phys Chem B. 2013 May 30;117(21):6339-51. doi: 10.1021/jp400241q. Epub 2013 May 20. PubMed PMID: 23656309. 9: Shirako J, Kawasaki M, Komine K, Kunisue Y, Terada M, Sasaki C, Irie W, Murakami C, Tonooka K, Tomobe K, Shinozuka T. Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry. Forensic Sci Int. 2013 Apr 10;227(1-3):100-2. doi: 10.1016/j.forsciint.2012.11.016. Epub 2012 Dec 27. PubMed PMID: 23273940. 10: Starek M, Krzek J. Quantification of Isoxicam in the Presence of Related Compounds by TLC-Densitometry. Acta Chim Slov. 2012 Jun;59(2):315-21. PubMed PMID: 24061247. 11: Buckley CE, Marguerie A, Roach AG, Goldsmith P, Fleming A, Alderton WK, Franklin RJ. Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects. Neuropharmacology. 2010 Sep;59(3):149-59. doi: 10.1016/j.neuropharm.2010.04.014. Epub 2010 May 5. PubMed PMID: 20450924. 12: Tamasi G, Casolaro M, Magnani A, Sega A, Chiasserini L, Messori L, Gabbiani C, Valiahdi SM, Jakupec MA, Keppler BK, Hursthouse MB, Cini R. New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. J Inorg Biochem. 2010 Aug;104(8):799-814. doi: 10.1016/j.jinorgbio.2010.03.010. Epub 2010 Mar 27. PubMed PMID: 20447694. 13: Rodríguez-Barrientos D, Rojas-Hernández A, Gutiérrez A, Moya-Hernández R, Gómez-Balderas R, Ramírez-Silva MT. Determination of pKa values of tenoxicam from 1H NMR chemical shifts and of oxicams from electrophoretic mobilities (CZE) with the aid of programs SQUAD and HYPNMR. Talanta. 2009 Dec 15;80(2):754-62. doi: 10.1016/j.talanta.2009.07.058. Epub 2009 Aug 5. PubMed PMID: 19836548. 14: Lee HW, Ji HY, Kim HY, Lee KC, Lee HS. Liquid chromatography-tandem mass spectrometry method for the determination of meloxicam and its metabolite 5-carboxymeloxicam in human plasma. Bioanalysis. 2009 Apr;1(1):63-70. doi: 10.4155/bio.09.10. PubMed PMID: 21083189. 15: Rezaei B, Mallakpour S, Majidi N. Solid-phase molecularly imprinted pre-concentration and spectrophotometric determination of isoxicam in pharmaceuticals and human serum. Talanta. 2009 Apr 30;78(2):418-23. doi: 10.1016/j.talanta.2008.11.042. Epub 2008 Dec 3. PubMed PMID: 19203603. 16: Tamasi G, Serinelli F, Consumi M, Magnani A, Casolaro M, Cini R. Release studies from smart hydrogels as carriers for piroxicam and copper(II)-oxicam complexes as anti-inflammatory and anti-cancer drugs. X-ray structures of new copper(II)-piroxicam and -isoxicam complex molecules. J Inorg Biochem. 2008 Oct;102(10):1862-73. doi: 10.1016/j.jinorgbio.2008.06.009. Epub 2008 Jun 20. PubMed PMID: 18667239. 17: Hinz B, Brune K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci. 2008 Aug;29(8):391-7. doi: 10.1016/j.tips.2008.06.004. Epub 2008 Jul 6. PubMed PMID: 18606461. 18: Kim YH, Ji HY, Park ES, Chae SW, Lee HS. Liquid chromatography-electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasma. Arch Pharm Res. 2007 Jul;30(7):905-10. PubMed PMID: 17703745. 19: Cini R, Tamasi G, Defazio S, Hursthouse MB. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. J Inorg Biochem. 2007 Aug;101(8):1140-52. Epub 2007 May 10. PubMed PMID: 17592742. 20: Ji HY, Lee HW, Kim YH, Jeong DW, Lee HS. Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):214-9. Epub 2005 Oct 5. PubMed PMID: 16169293.